What was the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing was to report Gilead Sciences, Inc.'s entry into a material definitive agreement, specifically the sale of an additional $300 million aggregate principal amount of convertible senior notes due 2014 and 2016, and related hedging and warrant transactions.

How much capital did Gilead raise with these additional notes, and what will it be used for?

Gilead raised approximately $295.5 million in net proceeds from the sale of the additional $300 million in convertible senior notes. The filing does not explicitly state the use of proceeds, but such capital raises are typically for general corporate purposes, research and development, or strategic initiatives.

What is the potential dilutive effect of these transactions on Gilead's stock?

The company entered into convertible note hedge transactions (purchased call options) to generally reduce the potential dilution upon conversion of the notes. However, the sale of warrants could have a dilutive effect if the market price of Gilead's common stock exceeds the strike prices of these warrants.

Are these convertible notes or warrants publicly traded?

No, the convertible senior notes and the underlying common stock issuable upon conversion, as well as the sold warrants and their underlying common stock, were issued in private placements. They have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States without registration or an applicable exemption.

GILD 8-K: Material Agreements, Financial Events & More

Summary

Gilead Sciences, Inc. (GILD) filed an 8-K on August 10, 2010, reporting on the significant issuance of additional convertible senior notes and related hedging transactions. Specifically, the company sold an additional $150 million of 1.00% Convertible Senior Notes due 2014 and $150 million of 1.625% Convertible Senior Notes due 2016. These issuances represent the exercise of an option by the initial purchasers, bringing the total principal amount of these convertible notes sold to $2.5 billion. The net proceeds from this additional issuance were approximately $295.5 million. In conjunction with the note sale, Gilead entered into convertible note hedge transactions (purchased call options) to mitigate potential dilution from conversion and sold warrants. These transactions were designed to manage the dilutive impact on Gilead's common stock. Investors should note that these securities were issued in private placements and are not registered under the Securities Act, subject to exemptions for qualified institutional buyers. The filing details the terms of the notes, including interest rates, maturity dates, conversion prices, and conditions for conversion, as well as the mechanics of the hedging and warrant agreements.

Key Highlights

1Gilead Sciences issued an additional $300 million in aggregate principal amount of convertible senior notes ($150M due 2014 and $150M due 2016), bringing the total issuance to $2.5 billion.
2Net proceeds from this additional note issuance were approximately $295.5 million.
3The company entered into convertible note hedge transactions (purchased call options) covering approximately 6.6 million shares to offset potential dilution from note conversions.
4Gilead also sold warrants to acquire approximately 6.6 million shares of common stock, which could have a dilutive effect if their strike prices are exceeded.
5The Additional 2014 Notes have a 1.00% coupon, mature May 1, 2014, and are convertible at an initial price of approximately $45.08 per share.
6The Additional 2016 Notes have a 1.625% coupon, mature May 1, 2016, and are convertible at an initial price of approximately $45.41 per share.
7Both note issuances and the sold warrants were conducted through private placements under exemptions from registration requirements.

GILEAD SCIENCES, INC. 8-K Report, Material Agreement (Aug 11, 2010)

Summary

Key Highlights

Frequently Asked Questions